Drug Database
Back to search

Poland· PL-100521854

Hympavzi

A other systemic hemostatics product containing marstacimabum, registered in Poland by Pfizer Europe MA EEIG. The same ATC class is registered in 3 of our 19 countries.

ATC B02BX

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedHympavziATCB02BXREGISTER NO.PL-100521854PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about marstacimabumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Marstacimabum is registered in 3 of 19 countries.

Countries holding a registration under ATC B02BX (other systemic hemostatics), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 3 of them publish a price we can compare per daily dose
Search marstacimabum products by name

Marstacimabum · ATC B02BX

3 / 19 countries

  • Polandprice
  • Switzerlandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Marstacimabum
Manufacturer
Pfizer Europe MA EEIG
Country
Poland (PL)
ATC code
B02BX
ATC class
Other systemic hemostatics
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05415062127490
  • gtin
    05415062132524

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Marstacimabum in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All marstacimabum products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Hympavzi
  • Liechtenstein · Hympavzi
  • Norway · Hympavzi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/3c217d0e-d026-48f9-b63c-0bb7343daf39
GET /v1/drugs/3c217d0e-d026-48f9-b63c-0bb7343daf39?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań we wstrzykiwaczu",
  "source": "urpl",
  "strength": "150 mg/ml",
  "packaging": "05415062127490 ¦ Rpz ¦ EU/1/24/1874/002 ¦ 162924\n1 wstrzykiwacz 1 ml\n¦ UR/Z/4c/175/25 - 05415062127490\n05415062132524 ¦ Rpz ¦ EU/1/24/1874/002 ¦ 163897\n1 wstrzykiwacz 1 ml",
  "substance": "Marstacimabum 150 mg/ml",
  "common_name": "Marstacimabum",
  "pl_product_id": "100521854",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about marstacimabum.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console